TW

Twist Bioscience Corporation

TWSTHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$376.6M
+20.3% YoY
Net Income
-$77.7M
+62.8% YoY
EBITDA
-$111.4M
+22.9% YoY
Free Cash Flow
-$58.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Jul 10 MACD Negative CrossoverHistogram -1.1030, negative momentum
Jul 9 MACD Negative CrossoverHistogram -0.8694, negative momentum
About Twist Bioscience Corporation

Part of the healthcare sector, Twist Bioscience Corporation (TWST) is listed under Diagnostics & Research. With a market capitalization of $5.84B, it sits in mid-cap territory. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Key stats
Market Cap$5.84B
Fwd P/E-122.95
EPS$-1.36
Beta2.12
52W Change+166.9%
ROE-18.2%
Analysis

The balance sheet looks solid with $171.7M in cash comfortably exceeding the $110.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$58.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $203.6M (2022) to $376.6M (2025), reflecting a 85% increase over the period.

With a beta above 1.5, TWST tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Twist Bioscience Corporation and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms